Bristol-Myers Squibb Gross Profit 2006-2019 | BMY

Bristol-Myers Squibb annual/quarterly gross profit history and growth rate from 2006 to 2019. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Bristol-Myers Squibb gross profit for the quarter ending September 30, 2019 was $4.197B, a 3.81% increase year-over-year.
  • Bristol-Myers Squibb gross profit for the twelve months ending September 30, 2019 was $16.837B, a 8.63% increase year-over-year.
  • Bristol-Myers Squibb annual gross profit for 2018 was $16.014B, a 9.07% increase from 2017.
  • Bristol-Myers Squibb annual gross profit for 2017 was $14.682B, a 1.55% increase from 2016.
  • Bristol-Myers Squibb annual gross profit for 2016 was $14.458B, a 14.28% increase from 2015.
Bristol-Myers Squibb Annual Gross Profit
(Millions of US $)
2018 $16,014
2017 $14,682
2016 $14,458
2015 $12,651
2014 $11,947
2013 $11,766
2012 $13,011
2011 $15,646
2010 $14,207
2009 $13,668
2008 $12,399
2007 $10,698
2006 $10,788
2005 $12,868
Bristol-Myers Squibb Quarterly Gross Profit
(Millions of US $)
Q3 2019 $4,197
Q2 2019 $4,281
Q1 2019 $4,076
Q4 2018 $4,283
Q3 2018 $4,043
Q2 2018 $4,079
Q1 2018 $3,609
Q4 2017 $3,768
Q3 2017 $3,675
Q2 2017 $3,575
Q1 2017 $3,664
Q4 2016 $3,837
Q3 2016 $3,617
Q2 2016 $3,665
Q1 2016 $3,339
Q4 2015 $3,335
Q3 2015 $2,972
Q2 2015 $3,150
Q1 2015 $3,194
Q4 2014 $3,292
Q3 2014 $2,914
Q2 2014 $2,898
Q1 2014 $2,843
Q4 2013 $3,168
Q3 2013 $2,890
Q2 2013 $2,940
Q1 2013 $2,768
Q4 2012 $3,116
Q3 2012 $2,749
Q2 2012 $3,198
Q1 2012 $3,948
Q4 2011 $4,087
Q3 2011 $3,938
Q2 2011 $3,953
Q1 2011 $3,668
Q4 2010 $3,697
Q3 2010 $3,518
Q2 2010 $3,491
Q1 2010 $3,501
Q4 2009 $3,600
Q3 2009 $3,471
Q2 2009 $3,440
Q1 2009 $3,157
Q4 2008 $1,925
Q3 2008 $3,620
Q2 2008 $3,533
Q1 2008 $3,321
Q4 2007 $1,535
Q3 2007 $3,123
Q2 2007 $3,063
Q1 2007 $2,977
Q4 2006 $1,596
Q3 2006 $2,689
Q2 2006 $3,303
Q1 2006 $3,200
Q4 2005 $3,013
Q3 2005 $3,284
Q2 2005 $3,406
Q1 2005 $3,165
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $97.676B $22.561B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $369.462B 16.01
Roche Holding AG (RHHBY) Switzerland $264.146B 0.00
Merck (MRK) United States $226.211B 17.52
Pfizer (PFE) United States $211.902B 12.60
Novartis AG (NVS) Switzerland $211.006B 17.81
Novo Nordisk (NVO) Denmark $134.360B 23.16
AbbVie (ABBV) United States $128.628B 10.08
AstraZeneca (AZN) United Kingdom $125.101B 22.60
Sanofi (SNY) France $115.265B 14.16
Eli Lilly (LLY) United States $114.870B 21.21
GlaxoSmithKline (GSK) United Kingdom $113.512B 13.75
Bayer (BAYRY) Germany $71.322B 10.56
H Lundbeck (HLUYY) Denmark $7.591B 10.95